Relationship between interleukin-1β and lipids in type 1 diabetic patients

Medical Science Monitor

Volumn 13, Issue 8, 2007, Pages

  Aribi, Mourad ^a,b   Moulessehoul, Soraya ^a   Kendouci Tani, Mohammed ^b   Benabadji, Ahmed Bakir ^b   Hichami, Aziz ^c   Khan, Naim Akhtar ^c  

^a UNIVERSITY OF SIDI BEL ABBES   (Algeria)

^b UNIVERSITY OF TLEMCEN   (Algeria)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

IL 1 ; Lipid anomalies; Type 1 diabetic patient

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN; THYROGLOBULIN; CYTOKINE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LIPID; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; SCHOOL CHILD; AUTOIMMUNE DISEASE; BIOSYNTHESIS; BLOOD; CHEMISTRY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METABOLISM; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

ADOLESCENT; ADULT; AUTOIMMUNE DISEASES; C-REACTIVE PROTEIN; CHILD; CYTOKINES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; LIPIDS; MALE; MODELS, STATISTICAL;

EID: 34548445956     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Kida K, Kaino Y, Ito T et al: Immunogenetics of insulin-dependent diabetes mellitus. Acta Pædiatr, 1999; Suppl. 427: 3-7
2. Eizirik DL, Mandrup-Poulsen T: A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia, 2001; 44: 2115-33
3. Rothe H, Ito Y, Kolb H: Disease resistant, NOD related strains reveal checkpoints of immunoregulation in the pancreas. J Mol Med, 2001; 79: 190-97
4. Kukreja A, Cost G, Marker J et al: Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest, 2000; 109: 131-40
5. Rabinovitch A, Suarez-Pinzon WL: Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol, 1998; 55: 1139-49
6. Yamada K, Takane-Gyotoku N, Yuan X et al: Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia, 1996; 39: 1306-12
7. Amrani A, Verdaguer J, Thiessen S et al: IL-1α, IL-1β, and INF-γ mark β cells for Fas-dependent destruction by diabetogenic CD4+ T lymphocytes. J Clin Invest, 2000; 105: 459-68
8. Eizirik DL, Darville MI: β-cell apoptosis and defense mechanisms: lessons from type 1 diabetes. Diabetes, 2001; 50(Suppl.1): S64-69
9. Sahdev I, Fort P, Herry A: Macrophage-released interleukin-1 in patients with type 1 diabetes mellitus. Acta Pædiatr, 1992; 81: 935-36
10. Cavaillon JM (ed.): Les cytokines. Paris Milan Barcelone, Masson, 1996
11. Auron PE, Webb AC: The structure and regulation of the human prointerleukin-1 beta gene. Ann Inst Past Immunol, 1987; 138: 462-68
12. Hao W, Myhre AP, Palmer JP: Nitric oxide mediates IL-1beta stimulation of heat shock protein but not IL-1beta inhibition of glutamic acid decarboxylase. Autoimmunity, 1999; 29: 93-101
13. El-Nawawy A, Soliman AT, El-Azzouni O et al: Interleukin-1-beta, tumor necrosis factor-alpha, insulin secretion and oral glucose tolerance in non-diabetic siblings of children with IDDM. Indian J Pediatr, 1998; 65: 455-60
14. Salvi GE, Beck JD, Offenbacher S: PGE2, IL-1β and TNF-α responses in diabetics as modifiers of periodontal disease expression. Ann Periodontol, 1998; 3: 40-50
15. Netea MG, Hancu N, Blok WL et al: Interleukin 1 beta, tumour necrosis factor-alpha and interleukin 1 receptor antagonist in newly diagnosed insulin-dependent diabetes mellitus: comparison to long-standing diabetes and healthy individuals. Cytokine, 1997; 9: 284-87
16. Lee SH, Brennan FR, Jacobs JJ et al: Human monocyte/macrophage response to cobalt-chromium corrosion products and titanium particles in patients with total joint replacements. J Orthop Rev, 1997; 15: 40-49
17. Giannoukakis N, Rudert WA, Ghivizzani SC et al: Adenoviral gene transfer of the interleukin-1 receptor antagonist protein to human islets prevents IL-1beta-induced beta-cell impairment and activation of islet cell apoptosis in vitro. Diabetes, 1999; 48: 1730-36
18. Feingold KR, Soued M, Adi S et al: Effect of interleukin-1 on lipid metabolism in the rat. Similarities to and differences from tumor necrosis factor. Arterioscler Thromb, 1991; 11: 495-500
19. Doxey DL, Nares S, Park B et al: Diabetes-induced impairment of macrophage cytokine release in a rat model: potential role of serum lipids. Life Sciences, 1998; 63: 1127-36
20. Iacopino AM: Diabetic periodontitis: possible lipid-induced defect in tissue repair through alteration of macrophage phenotype and function. Oral Dis, 1995; 1: 214-29
21. Vamvakopoulos JE, Green C: HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculo-protection. BMC Cardiovasc Disord, 2003; 3: 6
22. Navab M, Ananthramaiah GM, Reddy ST et al: The double jeopardy of HDL. Ann Med, 2005; 37: 173-78
23. Rohrer L, Hersberger M, von Eckardstein A: High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol, 2004; 15: 269-78
24. Su J, Georgiades A, Wu R et al: Antibodies of IgM subclass to phosphorylcholine and oxidized LDL are protective factors for atherosclerosis in patients with hypertension. Atherosclerosis, 2005 Nov 21; [Epub ahead of print]
25. Nofer JR, Walter M, Assmann G: Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence. Expert Rev Cardiovasc Ther, 2005; 3: 1071-86
26. Dayer JM: The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine, 2002; 69: 123-32
27. Erbaoci AB, Tarakçioolu M, Copkun Y et al: Mediators of inflammation in children with type 1 diabetes mellitus: cytokines in type 1 diabetic children. Clin Biochem, 2001; 34: 645-50
28. Campoy C, Baena RM, Blanca E et al: Effect of metabolic control on vitamin E nutritional status in children with type 1 diabetes mellitus. Clin Nut, 2003; 22: 81-86
29. Du Clos TW: Function of C-reactive protein. Ann Med, 2000; 32: 274-78
30. Schalkwijk CG, Poland DC, van Dijk W et al: Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia, 1999; 42: 351-57
31. Coulon J, Willems D, Dorchy H: Increase in C-reactive protein plasma levels during diabetes in infants and young adults. Presse Med, 2005; 34: 89-93
32. Galve-de Rochemonteix B, Wiktorowicz K, Kushner I, Dayer JM: C-reactive protein increases production of IL-1 alpha, IL-1 beta, and TNF-alpha, and expression of mRNA by human alveolar macrophages. J Leukoc Biol, 1993; 53: 439-45
33. Jos J, Thevenin M, Dumont G, Beyne P: Effect of metabolic control on plasma lipids and lipoproteins in insulin-dependent diabetes in children and adolescents. Diabete Metab, 1985; 11: 174-80
34. Abraha A, Schultz C, Konopelska-Bahu T et al: The Oxford Regional Prospective Study of Childhood Diabetes, Glycaemic control and familial factors determine hyperlipidaemia in early childhood diabetes. Diabetes Med, 1999; 16: 598-604
35. Bogalho P: Lipid disorders in children with insulin-dependent diabetes mellitus. Acta Med Port, 1998; 11: 683-90
36. Jenkins AJ, Lyons TJ, Zheng D et al: Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care, 2003; 26: 810-18